CleanRooms Online Article |  | |
AUGUST 18, 2008 -- MADISON, WI -- Cellectar, Inc., a privately held radiopharmaceutical company that designs, develops and manufactures products to detect, treat, and monitor human cancers, has completed commissioning its in-house manufacturing capability to meet clinical trial needs in compliance with Good Manufacturing Practice (GMP) requirements. This capability will allow Cellectar to initiate and complete its clinical trials while remaining independently able to develop and manufacture new radiopharmaceuticals beyond its lead candidate, CLR1404. Cellectar is now looking to expand its portfolio both with internal candidates and through potential in-licensing opportunities.
"We are extremely gratified to have achieved GMP compliance in our radiopharmaceutical manufacturing facility because it takes us one step closer toward clinical trials with our lead drug candidate, CLR1404," comments Neal Sandy, COO at Cellectar. "Our manufacturing technology and custom-designed building provide the flexibility and opportunity for our growing company to supply the radiopharmaceuticals needed to support our clinical program and to continue the development of additional molecules."
Source: Cellectar, Inc.
Visit Cellectar
|
Return to Previous Page
Webcasts | |
|
Sponsored White Papers Library | |
Recently Added White Papers
|
|
|
|
Current Issue 
Add RSS Feed